^
Association details:
| Biomarker: | KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128 |
|---|---|
| Cancer: | Sarcoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib
Excerpt:
An 83-year-old man presented...consistent with a diagnosis of angiosarcoma....The tumor was found to harbor 6 cancer-related somatic variants: VEGFR2 amplification (8x), VEGFR3 amplification (16x), MCL1 amplification (8x), TP53 R213*(2%) and H179Y (4%), and ARID1A Q2128* (14%)...we started the patient on a putative VEGFR inhibitor, sorafenib, at a dose of 400 mg daily in November 2012, with the dose increasing to 800 mg daily in December 2012. Despite observing 8x VEGFR2 amplification on comprehensive genomic profiling, this strategy was unsuccessful, as clinical disease progression was seen in a follow-up visit...
DOI:
10.6004/jnccn.2016.0058
